company background image
LSRM logo

CEL-SCI DB:LSRM Stock Report

Last Price

€0.96

Market Cap

€58.9m

7D

0.9%

1Y

-13.7%

Updated

09 Oct, 2024

Data

Company Financials +

LSRM Stock Overview

A clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States.

LSRM fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

CEL-SCI Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for CEL-SCI
Historical stock prices
Current Share PriceUS$0.96
52 Week HighUS$2.82
52 Week LowUS$0.92
Beta0.66
11 Month Change1.32%
3 Month Change-10.76%
1 Year Change-13.74%
33 Year Change-89.41%
5 Year Change-87.32%
Change since IPO-98.94%

Recent News & Updates

Recent updates

Shareholder Returns

LSRMDE BiotechsDE Market
7D0.9%2.0%-1.1%
1Y-13.7%-12.1%10.8%

Return vs Industry: LSRM underperformed the German Biotechs industry which returned -12.1% over the past year.

Return vs Market: LSRM underperformed the German Market which returned 10.8% over the past year.

Price Volatility

Is LSRM's price volatile compared to industry and market?
LSRM volatility
LSRM Average Weekly Movement9.6%
Biotechs Industry Average Movement6.4%
Market Average Movement4.9%
10% most volatile stocks in DE Market10.6%
10% least volatile stocks in DE Market2.4%

Stable Share Price: LSRM's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: LSRM's weekly volatility has decreased from 17% to 10% over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
1983n/aGeert Kerstencel-sci.com

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company’s lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer.

CEL-SCI Corporation Fundamentals Summary

How do CEL-SCI's earnings and revenue compare to its market cap?
LSRM fundamental statistics
Market cap€58.88m
Earnings (TTM)-€26.54m
Revenue (TTM)n/a

0.0x

P/S Ratio

-2.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LSRM income statement (TTM)
RevenueUS$0
Cost of RevenueUS$18.95m
Gross Profit-US$18.95m
Other ExpensesUS$10.15m
Earnings-US$29.10m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.47
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did LSRM perform over the long term?

See historical performance and comparison